New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Feb 15

PMID 35159167

Authors

Alessandro Audisio

Consuelo Buttigliero

Marco Donatello Delcuratolo

Elena Parlagreco

Marco Audisio

Antonio Ungaro

Rosario Francesco Di Stefano

Lavinia Di Prima

Fabio Turco

Marcello Tucci

Affiliations

Soon will be listed here.

Abstract

Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a non-negligible probability of recurrence and risk progression to muscle-invasive disease. NMIBC management requires a proper local resection and staging, followed by a risk-based treatment with intravesical agents. For many years, the current gold standard treatment for patients with intermediate or high-risk disease is transurethral resection of the bladder (TURB) followed by intravesical bacillus Calmette-Guérin (BCG) instillations. Unfortunately, in about half of high-risk patients, intravesical BCG treatment fails and NMIBC persists or recurs early. While radical cystectomy remains the gold standard for these patients, new therapeutic targets are being individuated and studied. Radical cystectomy in fact can provide an excellent long-term disease control, but can deeply interfere with quality of life. In particular, the enhanced immune checkpoints expression shown in BCG-unresponsive patients and the activity of immune checkpoints inhibitors (ICIs) in advanced bladder cancer provided the rationale for testing ICIs in NMIBC. Recently, pembrolizumab has shown promising activity in BCG-unresponsive NMIBC patients, obtaining FDA approval. Meanwhile multiple novel drugs with alternative mechanisms of action have proven to be safe and effective in NMIBC treatment and others are under investigation. The aim of this review is to analyse and describe the clinical activity of new emerging drugs in BCG-unresponsive NMIBC focusing on immunotherapy results.

Citing Articles

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies.

Lloyd K, Middelburg J, Ovcinnikovs V, Pencheva N, Kemper K, van Hall T Front Oncol. 2025; 15:1548446.

PMID: 39995843 PMC: 11847677. DOI: 10.3389/fonc.2025.1548446.

Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.

Yang X, Zheng H, Huang J, Liu Y, Li Y, Zhang B Int J Med Sci. 2024; 21(15):2870-2882.

PMID: 39628692 PMC: 11610333. DOI: 10.7150/ijms.100957.

Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy.

Choi H, Jeong S, Simo C, Bakenecker A, Liop J, Lee H Nat Commun. 2024; 15(1):9934.

PMID: 39548120 PMC: 11568179. DOI: 10.1038/s41467-024-54293-z.

Nanomedicine in Bladder Cancer Therapy.

Winnicka A, Brzeszczynska J, Saluk J, Wigner-Jeziorska P Int J Mol Sci. 2024; 25(19).

PMID: 39408718 PMC: 11476791. DOI: 10.3390/ijms251910388.

Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.

Taylor C, Patterson K, Friedman D, Bacot S, Feldman G, Wang T Cancers (Basel). 2024; 16(17).

PMID: 39272928 PMC: 11393896. DOI: 10.3390/cancers16173071.

References

Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M . Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000; 163(3):761-7. View

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View

Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H . Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells. Int J Urol. 2002; 9(1):29-35. DOI: 10.1046/j.1442-2042.2002.00415.x. View

Cambier S, Sylvester R, Collette L, Gontero P, Brausi M, van Andel G . EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2015; 69(1):60-9. DOI: 10.1016/j.eururo.2015.06.045. View

Ohadian Moghadam S, Nowroozi M . Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol. 2019; 90(6):e12818. DOI: 10.1111/sji.12818. View

Black P, Tangen C, Singh P, McConkey D, Lucia M, Lowrance W . Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023; 84(6):536-544. PMC: 10869634. DOI: 10.1016/j.eururo.2023.08.004. View

Bajorin D, Witjes J, Gschwend J, Schenker M, Valderrama B, Tomita Y . Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384(22):2102-2114. PMC: 8215888. DOI: 10.1056/NEJMoa2034442. View

Ludwig A, Moore J, Luo Y, Chen X, Saltsgaver N, ODonnell M . Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res. 2004; 64(10):3386-90. DOI: 10.1158/0008-5472.CAN-04-0374. View

Fukumoto K, Kikuchi E, Mikami S, Hayakawa N, Matsumoto K, Niwa N . Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy. Ann Surg Oncol. 2018; 25(8):2484-2491. DOI: 10.1245/s10434-018-6498-2. View

10.

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

11.

Ingersoll M, Albert M . From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol. 2013; 6(6):1041-53. DOI: 10.1038/mi.2013.72. View

12.

Shore N, Boorjian S, Canter D, Ogan K, Karsh L, Downs T . Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017; 35(30):3410-3416. PMC: 5648171. DOI: 10.1200/JCO.2017.72.3064. View

13.

Alvarez-Maestro M, Guerrero-Ramos F, Rodriguez-Faba O, Dominguez-Escrig J, Fernandez-Gomez J . Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp (Engl Ed). 2020; 45(2):93-102. DOI: 10.1016/j.acuro.2020.08.003. View

14.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

15.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

16.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

17.

Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P . Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006; 24(18):2729-34. DOI: 10.1200/JCO.2005.05.2720. View

18.

Larsen E, Joensen U, Poulsen A, Goletti D, Johansen I . Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS. 2019; 128(2):92-103. DOI: 10.1111/apm.13011. View

19.

Sylvester R, van der Meijden A, Witjes J, Kurth K . Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005; 174(1):86-91. DOI: 10.1097/01.ju.0000162059.64886.1c. View

20.

Teppema J, de Boer E, Steerenberg P, van der Meijden A . Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?. Urol Res. 1992; 20(3):219-28. DOI: 10.1007/BF00299721. View